SEP 07, 2016 7:30 AM PDT

Keynote Speaker: Challenges towards a Universal Influenza Virus Vaccine

Speaker
  • Professor and Chair Department of Microbiology, Professor in Department of Medicine and Infectious Diseases, Icahn School of Medicine at Mount Sinai
    Biography

      Peter Palese is a Professor of Microbiology and the Chair of the Department of Microbiology at the Icahn School of Medicine at Mount Sinai.  His research is in the area of RNA-containing viruses with a special emphasis on influenza viruses. Specifically, he established the first genetic maps for influenza A, B, and C viruses, identified the function of several viral genes, and defined the mechanism of neuraminidase inhibitors (which are now FDA-approved antivirals).  He was also a pioneer in the field of reverse genetics for negative strand RNA viruses, which allows the introduction of site-specific mutations into the genomes of these viruses.  This technique is crucial for the study of the structure/function relationships of viral genes, for investigation of viral pathogenicity and for development and manufacture of novel vaccines.  An improvement of this technique has been effectively used by him and his colleagues to reconstruct and study the pathogenicity of the highly virulent, but extinct, 1918 pandemic influenza virus.  Work in collaboration with Dr. Adolfo Garcia-Sastre has revealed that most negative strand RNA viruses possess proteins with interferon antagonist activity, enabling them to counteract the antiviral response of the infected host.   In recent years most of the efforts by Dr. Palese and by his collaborators at Mount Sinai, Dr. Adolfo Garcia-Sastre and Dr. Florian Krammer, have been directed at developing a Universal Influenza Virus Vaccine. Since the beginning of the year there has been a shift in directions as work on COVID-19 has become central to the efforts by Dr. Palese. Dr. Palese is a Member of the National Academy of Sciences, a Member of the National Academy of Medicine, a Fellow of the American Academy of Arts and Sciences, and a Fellow of the National Academy of Inventors


    Abstract

    Despite FDA-approved vaccines and antivirals, seasonal and pandemic influenza remains a serious threat associated with substantial morbidity and mortality.  The present modalities and vaccine approaches will be discussed and the difficulties one faces with the presently available formulations will be addressed. While annual seasonal influenza virus vaccination is frequently effective – albeit underutilized in most countries – a safe universal influenza virus vaccine providing broad and long-lasting immunity would represent a major breakthrough.  We have developed vaccine constructs which express chimeric hemagglutinins resulting in the redirection of the immune response away from the immunodominant (variant) head domain of the hemagglutinin toward the much more conserved stalk of the hemagglutinin and the highly conserved neuraminidase.  Such vaccine constructs work well in animal challenge models and await extensive clinical trials in humans. 
     


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    SEP 07, 2016 7:30 AM PDT

    Keynote Speaker: Challenges towards a Universal Influenza Virus Vaccine


    Specialty

    Gene Expression

    Research And Development

    Dna

    Big Data

    Cancer Research

    Tumor

    Biomarkers

    Cancer

    Oncology

    Earth Science

    Gene Sequencing

    University

    Drug Discovery

    Mass Cytometry

    Cell Culture

    Geography

    Asia50%

    Europe50%

    Registration Source

    Website Visitors100%

    Job Title

    Student50%

    Medical Laboratory Technician50%

    Organization

    Manufacturer - Other50%

    Academic Institution50%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more